Sinobiomed :: Pharmaceuticals for a Healthier World

Sinobiomed, Inc.

(also known in China as Shanghai Wanxing Bio-Pharmaceutical Co. Ltd)

Sinobiomed Inc. is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Based in Shanghai, Sinobiomed currently has 10 products approved or in development: three on the market, one awaiting approval, four in clinical trials and three in research and development. The Company’s products respond to a wide range of diseases and conditions, including:

Malaria Vaccine Update

Sinobiomed’s recombinant malaria candidate vaccine (PfCP2.9) targets the world’s most deadly malaria parasite (Plasmodium falciparum) at its most destructive stage—its rapid replication in human red blood cells. Patented in China, U.S. A., E.U. and Australia, PFCP2.9’s current research schedule calls for the application to the Chinese Food and Drug Administration (SFDA) for the Phase II Clinical trial in malaria endemic areas to be submitted by end of 2008.

Government support for malaria vaccine clinical trials

Sinobiomed’s 82% owned subsidiary, Shanghai Wanxing Bio-pharmaceuticals Co., Ltd., has been granted Chinese government funding of RMB 9 million (US$1.24 million) to continue the clinical trial of its recombinant malaria vaccine and advance its development with partner Second Military Medical University (SMMU). The funding is the largest the Chinese government has ever granted to a biopharmaceutical company. Read more...

recombinant baxtrobin update

Sinobiomed’s Recombinant Batroxobin (rBAT) is the world’s first batroxobin synthesized through gene recombination using a yeast expression method. Patented in China with the international patent applied for, rBAT is proven to be both safe and effective in reducing both the amount of bleeding and bleeding time during surgery. The Phase II Clinical trial is expected to be completed by February 2008. Read more...